The global cardiovascular therapeutics market in 2017 was estimated at USD 129 billion and projected to grow at CAGR of 2.3% to reach USD 141.38 billion by 2021. The top 10 cardiovascular drugs accounted for revenue of USD 11.55 billion in 2017. AstraZeneca/Shionogi /Chiesi, dominates the cardiovascular market, with its best-selling product, Crestor/Provisacor.
Sources: SEC filings, companies websites, and annual reports.igeahub.
高清图可阅读原文。
始发于微信公众号： 药物简讯